REGIMMUNE-LIMITED
REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on December 12, 2022.
This is an open label, single-arm Phase 2 study, evaluating the safety and efficacy of RGI-2001 for the prevention of aGVHD in subjects following allogeneic hematopoietic stem cell transplantation (HSCT). This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT. The incidence and severity of aGVHD was evaluated in patients treated with RGI-2001 in addition to standard GVHD prevention medications. “Based on the analysis, RGI-2001 showed reduced incidence of aGVHD with an excellent safety profile. I am thrilled that the RGI-2001 study results have been selected for oral presentation at the ASH meeting. We look forward to sharing future findings as we work to deliver breakthrough immune medicines by harnessing the power of regulatory T cells,” said Kenzo Kosuda, CEO at REGiMMUNE Limited.
Session Name: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease
Session Date and Time: Monday, December 12, 2022, 10:30 - 12:00 p.m. CT
Presentation time: 11:45 a.m. CT
Location: Ernest N. Morial Convention Center, 252-254 and online
Presenter: Yi-Bin Chen, MD
Publication Number: 774
Title: RGI-2001 Infusion for Prevention of Acute GVHD after Allogeneic Hematopoietic Cell Transplantation
Submission ID: 162512
About RGI-2001
RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT). Liposomal alpha-GalCer promotes tolerogenic immune cascades, resulting in the activation and expansion of regulatory T cells (Tregs). RGI-2001 is REGiMMUNE’s lead drug candidate currently in Phase 3 planning for the prophylaxis of acute graft-versus-host disease (aGVHD).
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221106005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release
One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select
Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 01:00:00 CEST | Press release
Company also recognizes key projects with Founders’ Honors, the Bentley-Envision winner for infrastructure sustainability, and the 2025 Bentley Educator of the Year (Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infr
Kinaxis Inc. to Host Third Quarter 2025 Financial Results Conference Call on November 6, 202516.10.2025 23:00:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2025. The call will be hosted on Thursday, November 6 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 5, 2025. CONFERENCE CALL DETAILSDATE: Thursday, November 6, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION:https://registrations.events/direct/Q4I91416498WEBCAST:https://events.q4inc.com/attendee/875765587 (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in informat
HCLTech and Zscaler Expand Partnership for AI-Powered Security and Network Transformation16.10.2025 20:13:00 CEST | Press release
HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of
Beyon Cyber and Haven Sign MoU to Launch Advanced AI-Powered SOC Capabilities in the UK and Worldwide16.10.2025 19:58:00 CEST | Press release
Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom